Skip to content

Technology
Pipeline
About Us
News
Investors
Contact

Technology
Pipeline
About Us
News
Investors
Contact

Press Releases

news hero image

Choose Year
Search Press Releases

Found 33 Results

February 13, 2026

Nasus Pharma Announces Closing of $15.0 Million Private Placement

February 10, 2026

Nasus Pharma Announces Pricing of $15.0 Million Private Placement

January 20, 2026

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

December 22, 2025

Nasus Pharma CEO Issues 2025 Letter to Shareholders

November 20, 2025

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

November 18, 2025

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

November 6, 2025

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

October 8, 2025

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

IR Contact

Mike Moyer
LifeSci Advisors
617-308-4306
IR@nasuspharma.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Science

Technology
Pipeline
NS003 Ondansetron
NS002 Epinephrine
NS001 Naloxone
Publications

Company

About us
Leadership
Board of Directors
Advisory Board
Contact

Investors

Investors Overview
Press Releases
Events
SEC Filings
Company Reports
Corporate Governance
Stock Information
Investor FAQs

© 2026 Nasus Pharma All rights reserved

Accessibility Statement
Cookies Policy
Privacy Policy
Terms And Conditions Of Use

Scroll to Top